– ABL Bio a GSK uzatvorili multiprogramovú dohodu o vývoji nových liekov na neurodegeneratívne ochorenia – Programy budú využívať technológiu platformy Grabody-B spoločnosti ABL Bio na efektívne podávanie molekúl cez hematoencefalickú bariéru – ABL Bio získa až 77 miliónov £ vo forme...
Hence then, the article about abl bio informuje o licencnej zmluve k platforme podavania liekov do mozgu grabody b so spolocnostou gsk na vyvoj novych liekov proti neurodegenerativnym ochoreniam was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( ABL Bio informuje o licenčnej zmluve k platforme podávania liekov do mozgu Grabody-B so spoločnosťou GSK na vývoj nových liekov proti neurodegeneratívnym ochoreniam )
Also on site :
- My Wife Doesn’t Know I Watched Her Cheat On Me. My Reaction Might Shock Us Both.
- The Good Ship Murder Christmas special cast: Meet the characters
- Eight fire crews tackling blaze at West Midlands Wetherspoon pub